Daewoong Pharma (069620) - Total Assets
Based on the latest financial reports, Daewoong Pharma (069620) holds total assets worth ₩2.26 Trillion KRW (≈ $1.53 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Daewoong Pharma - Total Assets Trend (2007–2024)
This chart illustrates how Daewoong Pharma's total assets have evolved over time, based on quarterly financial data. Also see Daewoong Pharma market capitalisation for the company's overall valuation and market capitalisation.
Daewoong Pharma - Asset Composition Analysis
Current Asset Composition (December 2024)
Daewoong Pharma's total assets of ₩2.26 Trillion consist of 31.0% current assets and 69.0% non-current assets. Review debt load of Daewoong Pharma to assess the company's total debt and financial obligations.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 5.2% |
| Accounts Receivable | ₩160.74 Billion | 8.1% |
| Inventory | ₩256.35 Billion | 13.0% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩285.86 Billion | 14.5% |
| Goodwill | ₩60.85 Billion | 3.1% |
Asset Composition Trend (2007–2024)
This chart illustrates how Daewoong Pharma's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 069620 live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Daewoong Pharma's current assets represent 31.0% of total assets in 2024, an increase from 0.0% in 2007.
- Cash Position: Cash and equivalents constituted 5.2% of total assets in 2024, down from 7.2% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, an increase from 0.0% in 2007.
- Asset Diversification: The largest asset category is intangible assets at 14.5% of total assets.
Daewoong Pharma Competitors by Total Assets
Key competitors of Daewoong Pharma based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
|
China | CN¥4.49 Billion |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
USA | $199.45 Million |
Daewoong Pharma - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.15 | 1.07 | 1.62 |
| Quick Ratio | 0.70 | 0.61 | 1.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩105.61 Billion | ₩36.10 Billion | ₩201.60 Billion |
Daewoong Pharma - Advanced Valuation Insights
This section examines the relationship between Daewoong Pharma's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.28 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 26.3% |
| Total Assets | ₩1.98 Trillion |
| Market Capitalization | $867.88 Million USD |
Valuation Analysis
Below Book Valuation: The market values Daewoong Pharma's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Daewoong Pharma's assets grew by 26.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Daewoong Pharma (2007–2024)
The table below shows the annual total assets of Daewoong Pharma from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩1.98 Trillion ≈ $1.34 Billion |
+26.26% |
| 2023-12-31 | ₩1.57 Trillion ≈ $1.06 Billion |
+0.15% |
| 2022-12-31 | ₩1.56 Trillion ≈ $1.06 Billion |
+10.47% |
| 2021-12-31 | ₩1.42 Trillion ≈ $959.05 Million |
+3.53% |
| 2020-12-31 | ₩1.37 Trillion ≈ $926.33 Million |
+9.73% |
| 2019-12-31 | ₩1.25 Trillion ≈ $844.17 Million |
+3.13% |
| 2018-12-31 | ₩1.21 Trillion ≈ $818.54 Million |
-0.47% |
| 2017-12-31 | ₩1.21 Trillion ≈ $822.39 Million |
+6.01% |
| 2016-12-31 | ₩1.14 Trillion ≈ $775.75 Million |
+21.19% |
| 2015-12-31 | ₩944.53 Billion ≈ $640.09 Million |
+36.05% |
| 2014-12-31 | ₩694.26 Billion ≈ $470.49 Million |
+19.90% |
| 2013-12-31 | ₩579.01 Billion ≈ $392.39 Million |
+20.04% |
| 2012-12-31 | ₩482.34 Billion ≈ $326.88 Million |
-3.23% |
| 2011-12-31 | ₩498.46 Billion ≈ $337.80 Million |
+2.51% |
| 2008-12-31 | ₩486.24 Billion ≈ $329.52 Million |
+23.79% |
| 2007-12-31 | ₩392.81 Billion ≈ $266.20 Million |
-- |
About Daewoong Pharma
Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplem… Read more